| Antibioticorganism |
OX2 μg |
E15 μg |
DA2 μg |
CRO30 μg |
CIP5 μg |
SXT5 μg |
AMC20-10 μg |
CN10 μg |
CPD30 μg |
CAZ30 μg |
CTX30 μg |
ESBL |
iMLSB |
|
Staphylococcs aureus (n=30) |
18 (60%) |
13 (43.3%) |
24 (80%) |
12 (40%) |
23 (77%) |
7 (23.3%) |
22 (73.3%) |
NT |
NT |
NT |
NT |
NT |
4(13%)
|
| Staphylococcus epidermidis (n=10) |
NT |
9 (56.2%) |
12 (75%) |
3 (19%) |
13 (81.3%) |
2 (12.5%) |
11 (68.8%) |
NT |
NT |
NT |
NT |
NT |
1(6.25%)
|
| E.coli (n=1) |
NT |
NT |
NT |
1 (100%) |
1 (100%) |
NT |
0 (0%) |
1 (100%) |
0 (0%) |
1 (100%) |
1 (100%) |
0(0%) |
NT
|
| Proteus
Mirabilis (n=1) |
NT |
NT |
NT |
1 (100%) |
0 (0%) |
NT |
1 (100%) |
1 (100%) |
0 (0%) |
0 (0%) |
1 (100%) |
1(100%) |
NT
|
| MRSA (n=12) |
0 (0%) |
6 (50%) |
11 (91%) |
4 (33.3%) |
9 (75%) |
4 (33.3%) |
9 (75%) |
NT |
NT |
NT |
NT |
NT |
2 (16.6%) |
Keys
NT-Not tested; ESBL-Extended Spectrum Beta Lactamases; iMLSB-Inducible Macrolide Lincomycin Streptogramin B-OX-Oxacillin, 0020.
E-Erythromycin, DA-Clindamycin; CRO-Ceftriaxone; CIP-Ciprofloxacin; SXT-Trimethoprim Sulphamethoxazole.
AMC-Amoxicillin clavulanic acid; CN-Gentamycin; CPD-Cefpodoxime; CAZ-Ceftazidime; CTX-Cefotaxime. |
